OBJECTIVES: To develop and validate selective screening criteria for asymptomatic Chlamydia trachomatis infections in the general population. METHODS:11,505 people, aged 15-40 years, registered in 16 general practices in Amsterdam were invited to return by mail a home obtained first void urine sample and a questionnaire. Participants were randomly allocated into a development group (75%) or a validation group (25%). C trachomatis infection was determined by the ligase chain reaction. In the development group a set of criteria was identified by means of stepwise logistic regression analysis. The diagnostic accuracy (area under the ROC curve; AUC) and sensitivity, and the corresponding percentage of people selected for screening were calculated. The criteria developed in this study were applied to the validation group. RESULTS: The prevalence of asymptomatic C trachomatis infections among men was found to be 2.4% (1.7-3.0), and among women 2.8% (2.2-3.4). Screening men, based on Surinam/Antillean origin and painful micturition, yielded an AUC of 0.58 (0.55-0.60). Screening women, based on Surinam/Antillean origin, new sex partner in the previous 2 months, and unmarried/not cohabiting, yielded an AUC of 0.67 (0.65-0.69). Application of the criteria for men to the validation group yielded an AUC of 0.53 (0.48-0.57); by screening 10% of the men, 15% of the cases were detected. The AUC of the criteria for women in the validation group was 0.58 (0.54-0.61); by screening 51% of the women, 63% of the cases were detected. CONCLUSION: The prevalence of asymptomatic C trachomatis infections in Amsterdam is less than 3%. No suitable selective screening criteria for the general population could be identified.
RCT Entities:
OBJECTIVES: To develop and validate selective screening criteria for asymptomatic Chlamydia trachomatis infections in the general population. METHODS: 11,505 people, aged 15-40 years, registered in 16 general practices in Amsterdam were invited to return by mail a home obtained first void urine sample and a questionnaire. Participants were randomly allocated into a development group (75%) or a validation group (25%). C trachomatis infection was determined by the ligase chain reaction. In the development group a set of criteria was identified by means of stepwise logistic regression analysis. The diagnostic accuracy (area under the ROC curve; AUC) and sensitivity, and the corresponding percentage of people selected for screening were calculated. The criteria developed in this study were applied to the validation group. RESULTS: The prevalence of asymptomatic C trachomatis infections among men was found to be 2.4% (1.7-3.0), and among women 2.8% (2.2-3.4). Screening men, based on Surinam/Antillean origin and painful micturition, yielded an AUC of 0.58 (0.55-0.60). Screening women, based on Surinam/Antillean origin, new sex partner in the previous 2 months, and unmarried/not cohabiting, yielded an AUC of 0.67 (0.65-0.69). Application of the criteria for men to the validation group yielded an AUC of 0.53 (0.48-0.57); by screening 10% of the men, 15% of the cases were detected. The AUC of the criteria for women in the validation group was 0.58 (0.54-0.61); by screening 51% of the women, 63% of the cases were detected. CONCLUSION: The prevalence of asymptomatic C trachomatis infections in Amsterdam is less than 3%. No suitable selective screening criteria for the general population could be identified.
Authors: S A Morré; I G van Valkengoed; A de Jong; A J Boeke; J T van Eijk; C J Meijer; A J van den Brule Journal: J Clin Microbiol Date: 1999-04 Impact factor: 5.948
Authors: L Grun; J Tassano-Smith; C Carder; A M Johnson; A Robinson; E Murray; J Stephenson; A Haines; A Copas; G Ridgway Journal: BMJ Date: 1997-07-26
Authors: J W Mouton; R Verkooyen; W I van der Meijden; T H van Rijsoort-Vos; W H Goessens; J A Kluytmans; S D Deelen; A Luijendijk; H A Verbrugh Journal: J Clin Microbiol Date: 1997-06 Impact factor: 5.948
Authors: C A Gaydos; M R Howell; B Pare; K L Clark; D A Ellis; R M Hendrix; J C Gaydos; K T McKee; T C Quinn Journal: N Engl J Med Date: 1998-09-10 Impact factor: 91.245
Authors: M Puolakkainen; E Hiltunen-Back; T Reunala; S Suhonen; P Lähteenmäki; M Lehtinen; J Paavonen Journal: J Clin Microbiol Date: 1998-06 Impact factor: 5.948
Authors: I G van Valkengoed; M J Postma; S A Morré; A J van den Brule; C J Meijer; L M Bouter; A J Boeke Journal: Sex Transm Infect Date: 2001-08 Impact factor: 3.519
Authors: H M Götz; J E A M van Bergen; I K Veldhuijzen; J Broer; C J P A Hoebe; E W Steyerberg; A J J Coenen; F de Groot; M J C Verhooren; D T van Schaik; J H Richardus Journal: Sex Transm Infect Date: 2005-02 Impact factor: 3.519
Authors: Robert L Cook; Lars Østergaard; Sharon L Hillier; Pamela J Murray; Chung-Chou H Chang; Diane M Comer; Roberta B Ness Journal: Sex Transm Infect Date: 2007-02-14 Impact factor: 3.519
Authors: Irene G M van Valkengoed; Servaas A Morré; Adriaan J C van den Brule; Chris J L M Meijer; Lex M Bouter; Jacques Th M van Eijk; A Joan P Boeke Journal: Br J Gen Pract Date: 2002-08 Impact factor: 5.386
Authors: J M Pimenta; M Catchpole; P A Rogers; E Perkins; N Jackson; C Carlisle; S Randall; J Hopwood; G Hewitt; G Underhill; H Mallinson; L McLean; T Gleave; J Tobin; V Harindra; A Ghosh Journal: Sex Transm Infect Date: 2003-02 Impact factor: 3.519
Authors: Stephan P Verweij; Ouafae Karimi; Jolein Pleijster; Joseph M Lyons; Henry J C de Vries; Jolande A Land; Servaas A Morré; Sander Ouburg Journal: Pathog Dis Date: 2015-11-13 Impact factor: 3.166
Authors: V Verhoeven; D Avonts; A Meheus; H Goossens; M Ieven; S Chapelle; C Lammens; P Van Royen Journal: Sex Transm Infect Date: 2003-08 Impact factor: 3.519